Cover Image
市場調查報告書

腎纖維症 : 開發平台分析

Kidney Fibrosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251573
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
腎纖維症 : 開發平台分析 Kidney Fibrosis - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 131 Pages
簡介

腎臟中如果累積了細胞外基質,就會引起腎纖維症,這是以腎小球硬化症和尿道間質纖維化為特徵的進行性疾病。對腎臟機能也會有所危害。因素有外傷、傳染病、手術、環境要素,還有曝露在化學物質或放射線中。症狀有疼痛、排尿相關問題、噁心想吐等。可靠藥物及腎臟移植等來管理症狀。

本報告提供腎纖維症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。

腎纖維症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • AbbVie Inc.
  • Angion Biomedica Corp.
  • Bio-inRen
  • BioLineRx, Ltd.
  • BiOrion Technologies B.V.
  • Cellmid Limited
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GenKyoTex S.A.
  • GNI Group Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Isarna Therapeutics GmbH
  • Lpath, Inc.
  • MorphoSys AG
  • ProMetic Life Sciences Inc.
  • Raptor Pharmaceuticals Corp.
  • Regulus Therapeutics Inc.
  • SciFluor Life Sciences, LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ANG-3070
  • ANG-3586
  • ANG-4011
  • ANG-4021
  • BOT-191
  • BRN-1889
  • CAB-101
  • CGEN-856
  • CT-140
  • cysteamine DR
  • 腎纖維症轉動 Galectin-3 抑制劑
  • 組織腎纖維症治療藥
  • F-351
  • 高血壓性心肌病·腎纖維症轉動 Smad7 活性遺傳療法
  • GKT-136901
  • GRMD-02
  • ICG-001
  • INT-767
  • ISTH-0047
  • LJ-1888
  • Lpathomab
  • MOR-107
  • P-007
  • PBI-4050
  • PBI-4419
  • 面向肥胖症·骨關節炎·腎纖維症·亞伯氏症候群 BMP-7 活躍蛋白質
  • SAR-339375
  • 腎纖維症轉動小分子
  • 肥胖症·腎纖維症轉動 親環蛋白 D 阻礙小分子
  • 面向腫瘤學·腎纖維症·自體免疫疾病·腎纖維症·神經退化性疾病 SphK2 阻礙小分子
  • SOL-1
  • 腎纖維症轉動 BMP7 受體工作用合成[月太]

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8537IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 21 and 7 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively for Kidney Fibrosis.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kidney Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Kidney Fibrosis - Overview
    • Pipeline Products for Kidney Fibrosis - Comparative Analysis
  • Kidney Fibrosis - Therapeutics under Development by Companies
  • Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Kidney Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Kidney Fibrosis - Products under Development by Companies
  • Kidney Fibrosis - Products under Investigation by Universities/Institutes
  • Kidney Fibrosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Angion Biomedica Corp.
    • Bio-inRen
    • BiOrion Technologies B.V.
    • Cellmid Limited
    • Epigen Biosciences, Inc.
    • Evotec AG
    • Galectin Therapeutics, Inc.
    • GenKyoTex S.A.
    • Intercept Pharmaceuticals, Inc.
    • Isarna Therapeutics GmbH
    • Lpath, Inc.
    • MorphoSys AG
    • Pharmaxis Limited
    • ProMetic Life Sciences Inc.
    • Raptor Pharmaceutical Corp.
    • Regulus Therapeutics Inc.
    • Symic Biomedical, Inc.
    • Tobira Therapeutics, Inc.
    • Vascular Biogenics Ltd.
  • Kidney Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3586 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-4021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOT-191 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BRN-1889 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cenicriviroc mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CT-140 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cysteamine DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GKT-136901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICG-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INT-767 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-0047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LJ-1888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MOR-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBI-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-4820 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PXS-5033A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit SphK2 for Autoimmune Disorders, Chronic Kidney Disease, Fibrosis, Neurodegenerative Diseases and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOL-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-703 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kidney Fibrosis - Dormant Projects
  • Kidney Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
      • Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
      • Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
      • Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
      • Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
      • Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
      • Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
      • Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Kidney Fibrosis, H2 2016
  • Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Kidney Fibrosis - Pipeline by AbbVie Inc, H2 2016
  • Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
  • Kidney Fibrosis - Pipeline by Bio-inRen, H2 2016
  • Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
  • Kidney Fibrosis - Pipeline by Cellmid Limited, H2 2016
  • Kidney Fibrosis - Pipeline by Epigen Biosciences, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Evotec AG, H2 2016
  • Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by GenKyoTex S.A., H2 2016
  • Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Kidney Fibrosis - Pipeline by Lpath, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by MorphoSys AG, H2 2016
  • Kidney Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
  • Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H2 2016
  • Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Symic Biomedical, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Kidney Fibrosis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Kidney Fibrosis, H2 2016
  • Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top